Merus N.V. (MRUS) PT Raised to $95 at BMO Capital

BMO Capital analyst Etzer Darout raised the price target on Merus N.V. (NASDAQ: MRUS) to $95.00 (from $91.00) while maintaining a Outperform rating.

The analyst commented, "MRUS (a Top Pick) provided a business update, highlighting the development progress for petosemtamab (EGFR x LGR5 BiClonic). MRUS initiated the Phase 3 LiGeR-HN2 trial recently in 2/3L HNSCC and the company plans to present updated 2L+ data from the dose optimization cohort of the Phase 1/2 trial in 4Q. MRUS plans to initiate the Phase 3 LiGeR-HN1 trial in combination with pembrolizumab by year-end. MRUS projects cash runway into 2028 (into 2027 previously). Reiterate OP with a target price to $95
(from $91) based on our model updates."

You May Also Be Interested In

• Freedom Broker Upgrades PrimeEnergy Resource (PNRG) to Hold
• Mark Walter, Todd Boehly in talks to sell Chelsea stakes - FT
• BofA sees dollar weakness continuing with New Zealand dollar gains